Compound: Ciclesonide
SMILES: O=C1C=C2[C@]([C@H]3[C@@H](O)C[C@@]4([C@@]5(O[C@H](C6CCCCC6)O[C@@H]5C[C@H]4[C@@H]3CC2)C(=O)COC(=O)C(C)C)C)(C)C=C1
InChIKey: LUKZNWIVRBCLON-GXOBDPJESA-N
Synonyms: Ciclesonide, 126544-47-6, Alvesco, Omnaris, Zetonna, RPR251526, RPR-251526, Ciclesonida, DTXSID9046659, Alvesco 80, Alvesco 160, (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate, BI54903, DTXCID7026659, S59502J185, ciclesonidum, Aservo EquiHaler, RefChem:57392, R01AD13, R03BA08, 2-((1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo(10.8.0.02,?.0?,?.013,1?)icosa-14,17-dien-8-yl)-2-oxoethyl 2-methylpropanoate, Ciclesonide (Standard), Ciclesonide [INN], [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate, 141845-82-1, [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-Cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate, 2-{6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl}-2-oxoethyl 2-methylpropanoate, Osonase, Osonide, Omnair, RPR 251526, Alvesco HFA, Omnaris HFA, 2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl isobutyrate, Alvesco (TN), Omnaris (TN), Ciclesonide [USAN:INN], sobutyrate, BTR-15K, Ciclesonide (JAN/USAN/INN), BTR-15, TBN-15, Ciclesonide CRS, LUKZNWIVRBCLON-GXOBDPJESA-N, UNII-S59502J185, NCGC00167484-01, Zetonna (TN), Alvesco, Ciclesonide, BYK-20426, BY-9010, KS-1165, CICLESONIDE [MI], CICLESONIDE [JAN], CICLESONIDE [USAN], CICLESONIDE [VANDF], SCHEMBL3688, CICLESONIDE [MART.], CICLESONIDE [WHO-DD], B-9207-015, GTPL7469, orb1305357, orb3025781, el-87-6, CHEMBL2040682, CHEBI:31397, Ciclesonide, >=98% (HPLC), HY-B0625R, CICLESONIDE [ORANGE BOOK], WLZ3795, CICLESONIDE [EP MONOGRAPH], HMS3714N07, EX-A4195, HY-B0625, Tox21_112486, BDBM50247997, EBC-27297, MSK011037, s4646, Ciclesonide containing impurity A CRS, AKOS015994702, AC-1330, CCG-269962, DB01410, FC20428, MSK011037-1000A, NCGC00167972-01, Pregna-1,4-diene-3,20-dione, 16,17-(((R)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-, Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(R))-, Ciclesonide 100 microg/mL in Acetonitrile, C3701, CAS-141845-82-1, CS-0694790, NS00006507, C72110, D01703, Ciclesonide Solution in Acetonitrile, 1000ug/mL, EN300-19766990, SR-01000942227, Q5119448, SR-01000942227-1, BRD-K35245662-001-01-2, Ciclesonide, European Pharmacopoeia (EP) Reference Standard, (11?,16?)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione, (11beta,16alpha)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione, [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxo-ethyl] 2-methylpropanoate, 2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl i, 2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl 2-methylpropanoate, 2-[(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-8-cyclohexyl-5-hydroxy-4a,6a-dimethyl-2-oxo-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-phenanthro[1',2':1,2]cyclopenta[3,4-d][1,3]dioxol-6b-yl]-2-oxoethyl 2-methylpropanoate, 2H-Naphth (2',1':4,5) indeno (1,2-d) (1,3) dioxole, pregna-1,4-diene-3,20-dione deriv., PREGNA-1,4-DIENE-3,20-DIONE, 16,17-(((R)-CYCLOHEXYLMETHYLENE)BIS(OXY))-11-HYDROXY-21-(2-METHYL-1-OXOPROPOXY)-, (11.BETA.,16.ALPHA.)
Theoretical properties:
molecular_formula: C32H44O7
molecular_weight: 540.7 g/mol
exact_mass: 540.30870374 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 6
heavy_atom_count: 39
topological_polar_surface_area: 99.1 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Ciclesonide is an organic molecular entity.
chembl: CICLESONIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.
It was patented in 1990 and approved for medical use in 2005. The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. It is on the World Health Organization's List of Essential Medicines.